{"id":"NCT00803361","sponsor":"Eli Lilly and Company","briefTitle":"Duloxetine for the Treatment of Generalized Anxiety Disorder","officialTitle":"Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2008-12-05","resultsPosted":"2010-12-17","lastUpdate":"2010-12-17"},"enrollment":210,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["Cymbalta","LY248686"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Duloxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder","primaryOutcome":{"measure":"Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint","timeFrame":"Baseline, Week 15","effectByArm":[{"arm":"Duloxetine","deltaMin":12.76,"sd":2.89},{"arm":"Placebo","deltaMin":13.56,"sd":2.96}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":7,"countries":["China"]},"refs":{"pmids":["22088518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":108},"commonTop":["Nausea","Dizziness","Constipation","Dry mouth","Somnolence"]}}